Thus, the fact that we cannot rule out complete biallelic loss of a gene of interest, such as BAP1, due to technical limitations and/or tumor heterogeneity, raises the possibility that, in the same patient, some tumors may be responsive to treatments designed to kill cells lacking BAP1, whereas others might only be partially responsive or totally unresponsive to such treatment. Here, BAP1 is linked to neoplasm.